TORONTO, ON – November 15, 2024 – The Canadian Nuclear Isotope Council (CNIC) is pleased to welcome Telix Pharmaceuticals, an international biopharmaceutical company, as its newest member organization. Telix Pharmaceuticals (“Telix”) is a commercial-stage biotechnology company producing therapeutic and diagnostic radiopharmaceuticals currently involved in over 20 clinical trials globally and creating innovative radiometal technology within the global isotope industry.
With a global headquarters in Melbourne, Australia, Telix’s primary workforce is based in the United States (U.S.) with its North American HQ outside of Indianapolis, Indiana. It also operates facilities in Europe, Japan, and – following the acquisition earlier this year of isotope production technology firm ARTMS Inc. (itself a spin-out from TRIUMF, Canada’s renowned particle accelerator centre) – a manufacturing footprint in Burnaby outside of Vancouver, BC.
Telix has received Health Canada approval for Illuccix, a PSMA-PET imaging agent for men with prostate cancer, which is also approved for use in Australia and the United States. Imaging agents such as Illuccix can help physicians detect and, subsequently, treat cancer sooner, ultimately seeking to achieve better outcomes for patients and reduce use of healthcare resources. Telix currently has two other radiopharmaceuticals under review in the U.S. (for prostate cancer and brain cancer (glioma) imaging), with plans to submit a late-stage kidney cancer imaging agent. Further regulatory submissions are planned in other strategically important markets, including Canada.
Telix’s membership with CNIC demonstrates its interest in the Canadian isotope industry. Its innovative work in Australia and across Europe and North America present significant opportunities for Canadian companies to collaborate and engage with Telix’s leadership and expand their reach on the global stage.
“As the newest member organization of the CNIC, Telix Pharmaceuticals joins a growing network of globally-based companies who are increasingly looking to Canada as a leader in isotope production. The CNIC is excited to support and learn from Telix’s new and innovative approaches to the production of radiopharmaceuticals,” said James Scongack, Chair of the CNIC. “We look forward to working with Telix Pharmaceuticals to foster innovation and support access to life-changing medical isotopes across Canada.”
“Canada is one of the leading countries worldwide in nuclear medicine and isotope production, and also an important market for Telix,” added Kevin Richardson, Chief Executive Officer, Precision Medicine, Telix. “I’m pleased that we have formalized our relationship with CNIC to help ensure that Canada remains a world leader in the production of life-saving isotopes and radiopharmaceuticals.”
To learn more about the work of Telix Pharmaceuticals, visit their website at https://telixpharma.com/
About the Canadian Nuclear Isotope Council
The Canadian Nuclear Isotope Council (CNIC) is an independent, not-for-profit advocacy and member services organization. The CNIC supports over 100 members from across science, academia, healthcare, and nuclear-sector organizations dedicated to maintaining Canada’s position as a global leader in the production of life-saving isotopes. The CNIC raises awareness and advocates for long-term policies that support health-care innovation and will save countless lives for decades to come.
For more information, please contact:
Melody Greaves
Manager, Business Strategy
Canadian Nuclear Isotope Council
melody.greaves@canadianisotopes.ca